This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kaye, D. M. Articles by Chin-Dusting, J. P. F. Search for Related Content PubMed PubMed Citation Articles by Kaye, D. M. Articles by Chin-Dusting, J. P. F. Related Collections Cardio-renal physiology/pathophysiology Endothelium/vascular type/nitric oxide Heart failure - basic studies

(Circulation. 2000;102:2707.)
© 2000 American Heart Association, Inc.

Clinical Investigation and Reports

In Vivo and In Vitro Evidence for Impaired Arginine Transport in Human Heart Failure

David M. Kaye, MBBS, PhD; Belinda A. Ahlers, BSc; Dominic J. Autelitano, PhD; Jaye P. F. Chin-Dusting, PhD

From the Baker Medical Research Institute and Cardiovascular Medicine, Alfred Hospital, Melbourne, Australia.

Correspondence to Dr David M. Kaye, Molecular Neurocardiology Laboratory, Baker Medical Research Institute, Commercial Road, Prahran, Victoria 3181, Australia. E-mail david.kaye{at}baker.edu.au

Background—The clinical features of congestive heart failure (CHF) result from a complex interaction between reduced ventricular function, neurohormonal activation, and impaired endothelial function. Although endothelial dysfunction has been well documented, the mechanisms that contribute to this abnormality remain unknown. Recent studies, however, indicate a potential therapeutic role for supplemental L-arginine, suggesting the presence of an underlying disorder of L-arginine metabolism.

Methods and Results—We used 2 complementary approaches to assess L-arginine transport in control subjects and patients with CHF. During a steady-state intra-arterial infusion of [³H]L-arginine (100 nCi/min), forearm clearance of [³H]L-arginine was significantly reduced in CHF patients compared with forearm kinetics in control subjects (64±2 versus 133±14 mL/min, P=0.002). In conjunction with this, [³H]L-arginine uptake by peripheral blood mononuclear cells (PBMCs) was also substantially reduced in heart failure patients compared with controls (V_max 10.1±1.3 versus 49.8±7.1 pmol/10⁵ cells per 5 minutes, P<0.001). In association with this finding, we observed a 76% (P<0.01) reduction in mRNA expression for the cationic amino acid transporter CAT-1, as assessed by ribonuclease protection assay.

Conclusions—These data document both in vivo and in vitro evidence for a marked depression of L-arginine transport in human CHF and therefore provide an explanation for the restorative actions of supplemental L-arginine on vascular function in CHF.

Key Words: amino acids • nitric oxide • radioisotopes • endothelium • cells

This article has been cited by other articles:

				M. Guazzi, R. Arena, and M. D. Guazzi Evolving changes in lung interstitial fluid content after acute myocardial infarction: mechanisms and pathophysiological correlates Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1357 - H1364. [Abstract] [Full Text] [PDF]

				Z. Yang, K. Venardos, E. Jones, B. J. Morris, J. Chin-Dusting, and D. M. Kaye Identification of a Novel Polymorphism in the 3'UTR of the L-Arginine Transporter Gene SLC7A1: Contribution to Hypertension and Endothelial Dysfunction Circulation, March 13, 2007; 115(10): 1269 - 1274. [Abstract] [Full Text] [PDF]

				W.-Z. Zhang, K. Venardos, J. Chin-Dusting, and D. M. Kaye Adverse Effects of Cigarette Smoke on NO Bioavailability: Role of Arginine Metabolism and Oxidative Stress Hypertension, August 1, 2006; 48(2): 278 - 285. [Abstract] [Full Text] [PDF]

				J. Steppan, S. Ryoo, K. H. Schuleri, C. Gregg, R. K. Hasan, A. R. White, L. J. Bugaj, M. Khan, L. Santhanam, D. Nyhan, et al. Arginase modulates myocardial contractility by a nitric oxide synthase 1-dependent mechanism PNAS, March 21, 2006; 103(12): 4759 - 4764. [Abstract] [Full Text] [PDF]

				T. Teerlink ADMA metabolism and clearance Vascular Medicine, May 1, 2005; 10(2_suppl): S73 - S81. [Abstract] [PDF]

				M. P. Schlaich, M. M. Parnell, B. A. Ahlers, S. Finch, T. Marshall, W.-Z. Zhang, and D. M. Kaye Impaired L-Arginine Transport and Endothelial Function in Hypertensive and Genetically Predisposed Normotensive Subjects Circulation, December 14, 2004; 110(24): 3680 - 3686. [Abstract] [Full Text] [PDF]

				M. M. Parnell, J. P. F. Chin-Dusting, J. Starr, and D. M. Kaye In vivo and in vitro evidence for ACh-stimulated L-arginine uptake Am J Physiol Heart Circ Physiol, July 1, 2004; 287(1): H395 - H400. [Abstract] [Full Text] [PDF]

				S.E.S. Miner, A. Al-Hesayen, S. Kelly, T. Benson, J.J. Thiessen, V.R. Young, and J.D. Parker L-Arginine Transport in the Human Coronary and Peripheral Circulation Circulation, March 16, 2004; 109(10): 1278 - 1283. [Abstract] [Full Text] [PDF]

				J. P.F. Chin-Dusting, B. A. Ahlers, D. M. Kaye, J. J. Kelly, and J. A. Whitworth L-Arginine Transport in Humans With Cortisol-Induced Hypertension Hypertension, June 1, 2003; 41(6): 1336 - 1340. [Abstract] [Full Text] [PDF]

				D. M. Kaye, M. M. Parnell, and B. A. Ahlers Reduced Myocardial and Systemic L-Arginine Uptake in Heart Failure Circ. Res., December 13, 2002; 91(12): 1198 - 1203. [Abstract] [Full Text] [PDF]